PM Modi visit USA
Only the mirror in my washroom and phone gallery see the crazy me : Sara Khan
Karnataka rain fury: Photos of flooded streets, uprooted trees
Cannes 2022: Deepika Padukone stuns at the French Riviera in Sabyasachi outfit
Ranbir Kapoor And Alia Bhatt's Wedding Pics - Sealed With A Kiss
Oscars 2022: Every Academy Award Winner
Shane Warne (1969-2022): Australian cricket legend's life in pictures
Photos: What Russia's invasion of Ukraine looks like on the ground
Lata Mangeshkar (1929-2022): A pictorial tribute to the 'Nightingale of India'
PM Modi unveils 216-feet tall Statue of Equality in Hyderabad (PHOTOS)
India Open Competition in Shotgun, organised by the National Rifle Association of India (N
- Hockey India names Amir Ali-led 20-man team for Junior Asia Cup
- Harmanpreet Singh named FIH Player of the Year, PR Sreejesh gets best goalkeeper award
- World Boxing medallist Gaurav Bidhuri to flag off 'Delhi Against Drugs' movement on Nov 17
- U23 World Wrestling Championship: Chirag Chikkara wins gold as India end campaign with nine medals
- FIFA president Infantino confirms at least 9 African teams for the 2026 World Cup
No approval for Covaxin, expert panel seeks more data from Bharat Biotech Last Updated : 01 Jan 2021 11:03:47 PM IST 
Covaxin The Subject Expert Committee of the Central Drug Standard Control Organisation on Friday has held that the data provided by Bharat Biotech for its coronavirus vaccine 'Covaxin' is not sufficient for grant of emergency use approval and has asked for more information, top sources said.
Earlier on Friday, the expert committee, which is tasked with vetting covid-19 vaccine proposals, recommended emergency licensure for the Serum Institute of India-manufactured 'Covishield'. It become the first vaccine to secure recommendation for emergency use in India.The Pune-based Serum Institute has partnered with Oxford-AstraZeneca for conducting clinical trials and manufacturing 'Covishield' while Bharat Biotech has collaborated with the Indian Council of Medical Research (ICMR) for 'Covaxin'.The committee had convened a meeting to take a call on the emergency use authorisation sought by the Serum Institute, Bharat Biotech and America's Pfizer for their coronavirus vaccines candidates.Pfizer was the first one to apply for the accelerated approval on December 4, followed by the Serum Insstitute and Bharat Biotech on December 6 and 7, respectively.The meeting comes a day before dry run of the vaccine is slated to commence in all the states and Union Territories to equip the administration in management of vaccine supply, storage and logistics including cold chain management.The Central government plans to vaccinate nearly 30 crore people in the first phase of drive. It will be offered to one crore healthcare workers, along with 2 crore frontline and essential workers and 27 crore elderly, mostly above the age of 50 years with co-morbidities.
IANS New Delhi For Latest Updates Please-
Join us on
Follow us on
What binds the two most talked about nations - India and Pakistan together? What makes the
Bollywood star Ranveer Singh and filmmaker Aditya Dhar seeked divine blessings at the Gold
LG Electronics Inc said on Wednesday that it will introduce new C with its artificial inte
172.31.16.186
